Bingdi Yan1, Junling Yang1, Yan Xie2, Xiaolei Tang3,4. 1. Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, Jilin, PR China. 2. Office of Institutional Research, University of Redlands, Redlands, CA, USA. 3. Department of Veterinary Biomedical Sciences, College of Veterinary Medicine, Long Island University, Brookville, NY, USA. 4. Division of Regenerative Medicine, Department of Medicine, Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Abstract
OBJECTIVES: A novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is causing the worldwide coronavirus disease 2019 (COVID-19) outbreak with high mortality. A unique finding among COVID-19 patients was a decline of eosinophil levels (eosinopenia). However, results from previous studies on the relationship between eosinopenia and disease severity were inconsistent. The objective of this study is to determine the relationship between eosinopenia and COVID-19 mortality as well as the clinical conditions that could potentially lead to mortality. METHODS: One hundred ninety patients diagnosed as moderate, severe, or critical COVID-19 at hospital admission were enrolled. Data collected from patients' medical records on the second day after hospital admission included medical histories, clinical symptoms, chest images of computed tomography (CT), laboratory examinations, and outcomes. RESULTS: Eosinophil levels were significantly lower in patients with critical disease, when compared to those with moderate and severe diseases. After controlled for confounding factors, ie, age, gender, hypertension, coronary heart disease, diabetes, and chronic lung disease, a progressive decline of eosinophil levels was independently associated with mortality. Moreover, eosinophil levels significantly and positively correlated with platelet and D-dimer levels but significantly and inversely correlated with serum levels of urea, creatinine, aspartate aminotransferase, lactate dehydrogenase, and creatine kinase. CONCLUSIONS: Eosinopenia, if progressively worsening, indicates that COVID-19 patients may progress to critical disease and have a significantly higher chance of mortality. Additionally, eosinopenia correlates with biomarkers of coagulation disorder and those of tissue damage in kidney, liver, and other tissues.
OBJECTIVES: A novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is causing the worldwide coronavirus disease 2019 (COVID-19) outbreak with high mortality. A unique finding among COVID-19 patients was a decline of eosinophil levels (eosinopenia). However, results from previous studies on the relationship between eosinopenia and disease severity were inconsistent. The objective of this study is to determine the relationship between eosinopenia and COVID-19 mortality as well as the clinical conditions that could potentially lead to mortality. METHODS: One hundred ninety patients diagnosed as moderate, severe, or critical COVID-19 at hospital admission were enrolled. Data collected from patients' medical records on the second day after hospital admission included medical histories, clinical symptoms, chest images of computed tomography (CT), laboratory examinations, and outcomes. RESULTS: Eosinophil levels were significantly lower in patients with critical disease, when compared to those with moderate and severe diseases. After controlled for confounding factors, ie, age, gender, hypertension, coronary heart disease, diabetes, and chronic lung disease, a progressive decline of eosinophil levels was independently associated with mortality. Moreover, eosinophil levels significantly and positively correlated with platelet and D-dimer levels but significantly and inversely correlated with serum levels of urea, creatinine, aspartate aminotransferase, lactate dehydrogenase, and creatine kinase. CONCLUSIONS: Eosinopenia, if progressively worsening, indicates that COVID-19 patients may progress to critical disease and have a significantly higher chance of mortality. Additionally, eosinopenia correlates with biomarkers of coagulation disorder and those of tissue damage in kidney, liver, and other tissues.
Authors: Amali E Samarasinghe; Rossana C N Melo; Susu Duan; Kim S LeMessurier; Swantje Liedmann; Sherri L Surman; James J Lee; Julia L Hurwitz; Paul G Thomas; Jonathan A McCullers Journal: J Immunol Date: 2017-03-10 Impact factor: 5.422
Authors: Yanaika S Sabogal Piñeros; Suzanne M Bal; Annemiek Dijkhuis; Christof J Majoor; Barbara S Dierdorp; Tamara Dekker; Esmée P Hoefsmit; Peter I Bonta; Daisy Picavet; Nicole N van der Wel; Leo Koenderman; Peter J Sterk; Lara Ravanetti; René Lutter Journal: Allergy Date: 2019-05-15 Impact factor: 13.146
Authors: Shrishtidhar Prasad; Suprava Patel; Ajoy K Behera; Dibakar Sahu; Seema Shah; Rachita Nanda; Eli Mohapatra Journal: J Family Med Prim Care Date: 2022-05-14
Authors: Rundk Ahmad Hwaiz; Sahar Mohammed Zaki Abdullah; Salah Tofik Jalal Balaky; Katan Sabir Ali; Mohammed Yousif Merza; Shakhawan Assad Khailani; Nazar Pauls Shabila Journal: Int J Immunopathol Pharmacol Date: 2022 Jan-Dec Impact factor: 3.219
Authors: Gorka Lasso; Saad Khan; Stephanie A Allen; Margarette Mariano; Catalina Florez; Erika P Orner; Jose A Quiroz; Gregory Quevedo; Aldo Massimi; Aditi Hegde; Ariel S Wirchnianski; Robert H Bortz; Ryan J Malonis; George I Georgiev; Karen Tong; Natalia G Herrera; Nicholas C Morano; Scott J Garforth; Avinash Malaviya; Ahmed Khokhar; Ethan Laudermilch; M Eugenia Dieterle; J Maximilian Fels; Denise Haslwanter; Rohit K Jangra; Jason Barnhill; Steven C Almo; Kartik Chandran; Jonathan R Lai; Libusha Kelly; Johanna P Daily; Olivia Vergnolle Journal: PLoS Comput Biol Date: 2022-01-18 Impact factor: 4.475